SrikanthReddyAmbatiMD

Pediatric Hematology & Oncology • New York, NY

Pediatric Sarcoma Oncology

Assistant Attending, MSKCC

Join to view full profile

Dr. Ambati is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ambati's full profile

Already have an account?

Office
1275 York Ave
New York, NY 10065
Phone+1 212-639-8171

Education & Training

Memorial Sloan Kettering Cancer CenterPost-Doctoral Fellowship, 2012 - 2014
New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 2009 - 2012
Nicklaus Children's HospitalResidency, Pediatrics, 2006 - 2009
Banaras Hindu University IOMClass of 2002

Certifications & Licensure

NY State Medical License 2011 - 2026
UT State Medical License 2009 - 2012
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Publications & Presentations

PubMed

Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: Primary analysis of the ELM-1 study.
Max S Topp, Matthew J Matasar, John N Allan, Stephen M Ansell, Jeffrey A Barnes
Blood. 2024-12-30
3 citations
Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relap...
Jurriaan Brouwer-Visser, Nathalie Fiaschi, Raquel P Deering, Kamil J Cygan, Darius Scott
Journal for Immunotherapy of Cancer. 2024-03-21
3 citations
Complete responses to odronextamab in two patients with diffuse large B-cell lymphoma refractory to chimeric antigen receptor T-cell therapy.
Matt Weinstock, Pavania Elavalakanar, Susan Bright, Srikanth R Ambati, Jurriaan Brouwer-Visser
British Journal of Haematology. 2022-11-01

Abstracts/Posters

Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
Srikanth R. Ambati, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti‑CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cel...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018